Cell & Gene Therapy Manufacturing and Commercialization part of Biotech Week Boston
September 20-23, 2021
Boston, Ma - Hybrid
FUJIFILM Diosynth Biotechnologies is excited to be attending Cell & Gene Therapy Manufacturing and Commercialization part of Biotech Week Boston, Live in person September 20-23 at the Boston Convention and Exhibition Center, Boston, Ma. Connect with the Commercial Development team in person or virtually to learn more about our capabilities and how we could help you advance and deliver tomorrow’s medicines.
Join our presentation Wednesday – September 22, 2021, 11:30 am EDT
Elie Hanania, Director of Upstream Process Development, FUJIFILM Diosynth Biotechnologies, Texas
Platform Manufacturing Approach for Adeno Associated Virus: Accelerated Time and Cost Saving
- The demand for viral vectors is expected to increase, fuelled by clinical successes in gene and cell therapy.
- Adeno associated virus (AAV) is one of the key viral vectors used for many gene therapy applications. Availability of several serotypes, favourable tropism for selective tissues and aggressive clinical development timelines have propelled the demand for high-titer AAV and hence the need for rapid process establishment/scale up
- The establishment of a platform approach for the development of processes for viral vector manufacturing, based on triple-transfection technology, will be presented and the benefits, challenges and limitations will also be discussed.
For the complete agenda and registration please click here